Public Joint-Stock Company "Human Stem Cells Institute" reported earnings results for the half year ended June 30, 2022. For the half year, the company reported revenue was RUB 519.89 million compared to RUB 556.75 million a year ago. Net income was RUB 25.02 million compared to RUB 19.71 million a year ago.

Basic earnings per share from continuing operations was RUB 0.29 compared to RUB 0.26 a year ago. Diluted earnings per share from continuing operations was RUB 0.29 compared to RUB 0.26 a year ago.